dlbcl

Showing 1 - 25 of 42

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)

Recruiting
  • DLBCL
  • Tafasitamab and Lenalidomide
  • Hangzhou, Zhejiang, China
    The First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022

Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

Not yet recruiting
  • Phase 1
  • +9 more
  • Oral MRT-2359
  • Scottsdale, Arizona
  • +7 more
Sep 16, 2022

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

Advanced Solid Tumor, DLBCL Trial in United States (RNK05047)

Recruiting
  • Advanced Solid Tumor
  • DLBCL
  • Atlanta, Georgia
  • +3 more
Aug 23, 2022

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Aug 19, 2022

DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

Not yet recruiting
  • DLBCL
  • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
  • Qingdao, Shandong, China
    the affiliated hospital of Qingdao University
Aug 18, 2022

DLBCL, DLBCL Trial in Worldwide (Zilovertamab vedotin, Rituximab, Gemcitabine)

Recruiting
  • DLBCL
  • Diffuse Large B-Cell Lymphoma
  • Zilovertamab vedotin
  • +4 more
  • Whittier, California
  • +15 more
Aug 12, 2022

DLBCL Trial in China (Orelabrutinib and Gemox)

Not yet recruiting
  • DLBCL
  • Orelabrutinib and Gemox
  • Chongqing, Chongqing, China
  • +7 more
Jul 5, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

DLBCL Trial in United States (MB-CART2019.1)

Recruiting
  • DLBCL
  • MB-CART2019.1
  • Gilbert, Arizona
  • +14 more
Jun 17, 2022

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Recruiting
  • DLBCL
  • +8 more
  • Cardiac MRI
  • Bonn, NRW, Germany
    University Hospital Bonn
Jun 11, 2022

Advanced Solid Tumor, NSCLC, Melanoma Trial in United States (AB308, Zimberelimab)

Recruiting
  • Advanced Solid Tumor
  • +9 more
  • Phoenix, Arizona
  • +20 more
May 2, 2022

Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

Not yet recruiting
  • Primary Extranodal Lymphoma
  • DLBCL
  • (no location specified)
Apr 6, 2022

Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 30, 2022

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
Mar 24, 2022

CLL/SLL, NHL, MCL Trial in United States (HMPL-760)

Recruiting
  • CLL/SLL
  • +8 more
  • Atlanta, Georgia
  • +3 more
Feb 24, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

DLBCL Trial in Belgium, France (Tafasitamab, Lenalidomide, Rituximab)

Recruiting
  • DLBCL
  • Brussels, Belgium
  • +14 more
Mar 3, 2022

DLBCL Trial in Seoul (Tislelizumab, Pemetrexed)

Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 15, 2022

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL Trial in

Enrolling by invitation
  • Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
  • +4 more
  • AUTO CAR T cell therapy
  • London, United Kingdom
  • +3 more
Feb 2, 2022

NHL, DLBCL Trial in Belgium, Netherlands (Atezolizumab)

Active, not recruiting
  • NHL
  • DLBCL
  • Antwerpen, Belgium
  • +31 more
Jan 19, 2022

B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL Trial in Stanford (Fludarabine, Cyclophosphamide, CD22 CAR)

Recruiting
  • B-ALL
  • +3 more
  • Stanford, California
    Stanford Medical Center
Jan 14, 2022

DLBCL, Lymphoma, B-Cell Trial in Rochester (Polatuzumab vedotin, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL
  • Lymphoma, B-Cell
  • Polatuzumab vedotin
  • +4 more
  • Rochester, New York
    University of Rochester
Jan 6, 2022

DLBCL, Neurotoxicity Syndromes Trial in United States (Defibrotide)

Terminated
  • DLBCL
  • Neurotoxicity Syndromes
  • Phoenix, Arizona
  • +4 more
Nov 10, 2021